- Home
- ENLV vs LRE Comparison
ENLV vs LRE Comparison
Compare ENLV & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLV
- LRE
- Stock Information
- Founded
- ENLV 2005
- LRE 2001
- Country
- ENLV Israel
- LRE Japan
- Employees
- ENLV N/A
- LRE N/A
- Industry
- ENLV Biotechnology: Pharmaceutical Preparations
- LRE
- Sector
- ENLV Health Care
- LRE
- Exchange
- ENLV Nasdaq
- LRE Nasdaq
- Market Cap
- ENLV 20.7M
- LRE 17.6M
- IPO Year
- ENLV 1995
- LRE 2023
- Fundamental
- Price
- ENLV $0.98
- LRE $1.25
- Analyst Decision
- ENLV Strong Buy
- LRE
- Analyst Count
- ENLV 2
- LRE 0
- Target Price
- ENLV $10.00
- LRE N/A
- AVG Volume (30 Days)
- ENLV 63.0K
- LRE 5.8K
- Earning Date
- ENLV 06-13-2025
- LRE 01-01-0001
- Dividend Yield
- ENLV N/A
- LRE N/A
- EPS Growth
- ENLV N/A
- LRE N/A
- EPS
- ENLV N/A
- LRE 0.29
- Revenue
- ENLV N/A
- LRE $117,804,154.00
- Revenue This Year
- ENLV N/A
- LRE N/A
- Revenue Next Year
- ENLV N/A
- LRE N/A
- P/E Ratio
- ENLV N/A
- LRE $4.44
- Revenue Growth
- ENLV N/A
- LRE 8.82
- 52 Week Low
- ENLV $0.81
- LRE $1.10
- 52 Week High
- ENLV $1.84
- LRE $13.76
- Technical
- Relative Strength Index (RSI)
- ENLV 53.70
- LRE 49.22
- Support Level
- ENLV $0.87
- LRE $1.11
- Resistance Level
- ENLV $0.91
- LRE $1.49
- Average True Range (ATR)
- ENLV 0.06
- LRE 0.13
- MACD
- ENLV 0.01
- LRE 0.00
- Stochastic Oscillator
- ENLV 90.31
- LRE 36.84
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.